Previous Close | 0.6600 |
Open | 0.6597 |
Bid | 0.5535 x 200 |
Ask | 0.6500 x 200 |
Day's Range | 0.5100 - 0.6863 |
52 Week Range | 0.1300 - 3.4600 |
Volume | |
Avg. Volume | 975,800 |
Market Cap | 29.399M |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4200 |
Earnings Date | Mar 28, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BCLI
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3b Trial Design Announced; SPA Submitted to the FDA On March 4, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented a poster at the MDA Clinical and Scientific Conference with an outline of the proposed design for a Phase 3b trial of NurOwn® (debamestrocel) in amyotrophic lateral sclerosis (ALS).
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#M201) outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS) at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida. The design is for a two-part, multicenter, Phase 3b study to assess the efficacy and safet
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).